06th January 2021
Consilium Strategic Communications Advises Arvelle Therapeutics From Inception Through Its Successful Acquisition by Angelini Pharma
London, 6 January 2021, Consilium Strategic Communications, a global leader in strategic healthcare communications and investor relations, is pleased to have advised Arvelle Therapeutics on its strategic communications since its inception and culminating in its acquisition by Angelini Pharma for a total aggregate valuation of up to $960 million.
Arvelle Therapeutics is an emerging biopharmaceutical company focused on bringing innovative solutions to patients suffering from CNS disorders. Since its founding in 2019, Arvelle’s management team has focused on bringing cenobamate to people with epilepsy in Europe. Following Angelini Pharma’s acquisition of Arvelle Therapeutics, Angelini Pharma will have the exclusive license to commercialize cenobamate in the European Union and other countries in the European Economic Area (Switzerland and the United Kingdom).
The team advising Arvelle Therapeutics at Consilium was Mary-Jane Elliott, Susan Stuart, Alex Harrison, Lindsey Neville, Carina Jurs and Kris Lam. Centerview Partners UK LLP acted as sole financial advisor and Sidley Austin LLP and NautaDutilh N.V. provided legal counsel to Arvelle Therapeutics during the acquisition.
“It has been a pleasure to work with the team at Arvelle. Since its launch in 2019, Arvelle has made significant progress towards launching cenobamate in Europe and we are delighted for the management team and company on securing this deal which has also created significant value for shareholders.”
Mary-Jane Elliott
Managing Partner of Consilium Strategic Communications“We are grateful to the team at Consilium for their strategic advice and guidance since we started working with them in 2019 and through this acquisition. They have been a close advisor to the senior management team and I have been impressed by the team’s sector knowledge and professionalism.”
Mark Altmeyer
President & CEO of Arvelle Therapeutics-ENDS-
For more information, please contact:
Consilium Strategic Communications
Mary-Jane Elliott / Amber Fennell
Tel: +44(0)20 3709 5700
Follow us: @consiliumhc
About Consilium Strategic Communications
Consilium Strategic Communications is a global leader in strategic healthcare communications and investor relations advisory with offices in Europe and across the US. Consilium's highly skilled team provides strategic, long-term advice to healthcare companies, Boards, senior decision makers and executives on critical communications and IR programmes and stakeholder challenges. The Company has established deep knowledge across all areas of the global healthcare sector through broad experience in representing international clients spanning the Fortune 500, FTSE100, FTSEurofirst 300 and FTSE250, through to discrete specialist reputation management projects.
